Evidence map›Paper›PMID 35832083›Full record

ArticleTheranostics2022

Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives.

Karolin Roemhild, Helena C Besse, Bi Wang, Quim Peña, Qingxue Sun, Daiki Omata, Burcin Ozbakir, Clemens Bos, Hans W Scheeren, Gert Storm and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Lysosome as a Chemical Reactor.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 5 countries.

Karolin RoemhildDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Helena C BesseDivision of Imaging and Oncology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Bi WangDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Quim PeñaDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Qingxue SunDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Daiki OmataDepartment of Pharmaceutics, Utrecht University, Utrecht, 3584 CG, The Netherlands.
Burcin OzbakirDepartment of Pharmaceutics, Utrecht University, Utrecht, 3584 CG, The Netherlands.
Clemens BosDivision of Imaging and Oncology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Hans W ScheerenDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Gert StormDepartment of Pharmaceutics, Utrecht University, Utrecht, 3584 CG, The Netherlands.
Josbert M MetselaarDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Haijun YuState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Ruth Knüchel-ClarkeInstitute of Pathology, Uniklinik RWTH Aachen, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Fabian KiesslingDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Chrit T W MoonenDivision of Imaging and Oncology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Roel DeckersDivision of Imaging and Oncology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Yang ShiDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Twan LammersDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
RWTH Aachen University · DEUniversitätsklinikum Aachen · DEShanghai Institute of Materia Medica · CNTeikyo University · JPUniversity of Twente · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsProdrugsDoxorubicinGlucuronidaseHumansDoxorubicinGlucuronidaseProdrugsCancerFocused ultrasoundHIFUProdrugsβ-glucuronidase

Identifiers

PMID35832083
PMCPMC9254251
OpenAlexW4285115454

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.